Gilead Extends Its Funding Support for the Gilead Sciences Research Centre at the Institute of Organic Chemistry & Biochemist...
May 05 2011 - 5:00AM
Business Wire
Gilead Sciences, Inc. (Nasdaq:GILD) today announced it has
extended its funding support of the Gilead Sciences Research Centre
at the Institute of Organic Chemistry and Biochemistry (IOCB) of
the Academy of Sciences of the Czech Republic for an additional
five years. Gilead will provide a $1.15 million annual donation to
IOCB in order to continue to fund the Research Centre’s operations
and ongoing research efforts. In July 2006, Gilead announced an
initial five-year annual donation to IOCB for the establishment and
support of the Research Centre. Gilead has the first option to
license inventions that result from the Research Centre’s
scientific programs and drug discovery efforts.
In 1991 and 1992, Gilead entered into license agreements with
IOCB in Prague and the Rega Institute for Medical Research,
Katholic University in Leuven, Belgium that cover a broad range of
biologically active nucleotide analogues. Several of these
nucleotide compounds discovered through a collaborative research
effort between Dr. Antonín Holý, IOCB, and Dr. Erik De Clercq, Rega
Institute, were developed by Gilead, resulting in Vistide®
(cidofovir injection) for the treatment of CMV retinitis in AIDS
patients, Viread® (tenofovir disoproxil fumarate) for the treatment
of HIV and chronic hepatitis B infection and Hepsera® (adefovir
dipivoxil) for the treatment of chronic hepatitis B.
“It has been 25 years since IOCB in collaboration with the Rega
Institute made the initial seminal discovery of the promising novel
class of broad-spectrum antiviral nucleotide analogue compounds
that, ultimately, have helped advance patient care for millions of
people with life-threatening diseases,” said John C. Martin,
Chairman and CEO, Gilead Sciences. “We are proud of our ongoing
collaboration with IOCB and are pleased to support the Research
Centre’s leadership role in exploring the important field of
nucleotide analogues as potential therapeutics for infectious
diseases and other unmet medical needs.”
“Gilead Sciences Research Centre in Prague is
an excellent opportunity for us to collaborate with an established
and productive industry partner. It opens up new horizons for
applied research at the Institute and at the same time extends the
legacy from the past excellent collaboration between Dr. Holý’s
team and Gilead. The generous support from Gilead helps us search
for new scientific paradigms and approaches that may help address
existing medical problems and also allows us to focus on new
exploratory research avenues that would otherwise be difficult to
pursue effectively,” said Dr. Zdenek Havlas, the Director of
IOCB.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company's mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Asia Pacific. For more information,
please visit www.gilead.com.
About IOCB
The Institute performs fundamental research in organic
chemistry, biochemistry and related disciplines oriented mostly to
medicinal, material and environmental applications. The Institute
is involved in university level education and supervises graduate
and post-doctoral studies.
Forward-Looking
Statement
This press release includes forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of
1995, that are subject to risks, uncertainties and other factors.
These risks, uncertainties and other factors could cause actual
results to differ materially from those referred to in the
forward-looking statements. The reader is cautioned not to rely on
these forward-looking statements. These and other risks are
described in detail in Gilead's Annual Report on Form 10-K for the
year ended December 31, 2010, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024